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Abstract: 
Incorporate both diagnostic and therapeutic functions into a single nanoscale system is an 
effective modern drug delivery strategy. Combine liposomes with Semiconductor quantum 
dots (QDs) have great potential to achieve such dual functions, referred to in this review as a 
liposomal QD hybrid system (L-QD). Here we review the recent literature dealing with the 
design and application of L-QD for advanced in bio-imaging and drug delivery. After a 
summary of L-QD synthesis process and evaluation of their properties, we will focus on their 
multifunctional applications, ranging from in vitro cell imaging to theranostic drug delivery 
approaches.  
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Introduction of liposomal quantum dot Hybrid delivery system 
The use of nanoparticles has increased in the areas of drug delivery[1, 2], cancer detection[3], 
and therapeutics[1, 4-7]. Quantum dots (QDs) are one of the most interesting examples due to 
unique optical characteristics that enable them to overcome the limitations of previously used 
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organic fluorophores[8, 9]. On the other hand, liposomes are nanoscale spherical vesicles 
composed of phospholipid bilayers[10]. The more recent proposition to combine liposomes 
with QDs not only increases biocompatibility of QDs, but also opens opportunities for 
creating theranostic nanoscale delivery systems, which can combine simultaneous therapeutic 
and imaging functions[11]. Combining QD with therapeutic agent in a liposomal delivery 
system allows the bio-distribution of the payload can be monitored in vivo, reducing the 
potential for unintended side effects of drug toxicity in healthy tissues. In addition, the use of 
such hybrid systems potentially allows clinicians to monitor the progress and efficacy of a 
therapy throughout the course of treatment[11]. In this review, we have focused on the 
liposomal QD hybrid system (L-QD), where imaging agent and therapeutic agent and can be 
co-delivered. 
Liposome based drug delivery system 
Liposomes were discovered by Alec D Bangham in the 1960s at the Babraham Institute, 
University of Cambridge[12, 13].Since their discovery, liposomes have been widely 
investigated, and are considered to be one of the most successful drug delivery systems. The 
first liposome formulation was composed solely of natural lipids; now liposomes can be 
created from cholesterol and natural or synthetic phospholipids with additional modification 
to prolong their in vivo circulation time[10]. In aqueous solutions, due to their amphipathic 
nature phospholipids have a strong tendency to form membranes[14]. Hydrophobic drugs/QDs 
can be enclosed in-between membranes, while hydrophilic drugs/QDs can be encapsulated 
inside central compartment. To improve the delivery of therapeutic molecules, surface 
modification of liposomes by the inclusion of hydrophilic carbohydrates, glycolipids or 
polymers, such as polyethylene glycol (PEG) can be used[15, 16]. The PEGylation of the 
liposomes would prolong the blood-circulation time while suppressing the uptake by the 
reticuloendothelial system (RES)[17, 18]. These long-circulating liposomes can passively 
accumulate in tumour site through the porous endothelium present in tumours—the enhanced 
permeability and retention (EPR) effect[16]. Or active targeting can be achieved by further 
modify the PEG terminus with functional molecules e.g. specific ligands or monoclonal 
antibodies[19-21]. 
Liposomes can vary from a few nanometres to several micrometres and may have one or 
more lipid bilayers. The sizing of liposome is a critical parameter which determines their 
therapeutic efficiency[22] and helps characterise liposomes. On the basis of their size and 
lamellarity, liposomes can be classified into one of three categories: multilamellar vesicles 
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(MLV), large unilamellar vesicles (LUV) and small unilamellar vesicles (SUV)[23]. MLV 
have an onion like structure with diameters of 1-5µm. SUV are typically 50nm in diameter 
while LUV range from 100-250nm or even larger[24]. There are several methods for the 
preparation of liposomes. One of the most widely used techniques for liposome synthesis is 
the thin-film hydration [10], where dry lipid film is hydrated by adding an aqueous buffer 
solution under agitation at temperature above the lipid transition temperature[25]. During this 
process hydrophilic drugs are entrapped by using the aqueous solution of these materials as 
hydrating fluid, while lipophilic drugs are solubilised in the organic solution of the 
constitutive lipid. However, using this method, large and nonhomogeneous MLVs have 
formed and further steps are needed to produce homogeneous SUV. The second method is 
solvent solvent-injection using either ether or ethanol. This method involves the dissolution 
of the lipids into either or ethanol, followed by the injection of the lipid solution into aqueous 
solution [26, 27]. The ether injection method has one advantage over ethanol injection method 
as ether is immiscible with water so can be removed directly during injection process by 
using warmed aqueous phases above the boiling point of the ether[25]. The third method is 
reverse-phase evaporation, which is based on the creation of inverted micelles. Briefly, the 
water-in-oil emulsion is formed by brief sonication of organic solvent containing 
phospholipids and aqueous buffer. Then the liposomes are shaped when the organic solvent is 
evaporated during continued rotary evaporation under reduced pressure[28].Other methods for 
liposomes preparation includes detergent removal[29], Spray-drying[30], freeze drying[31], and 
microfluidisation[32]. 
Drug loading into liposome can be attained either passively (i.e., the drug is encapsulated 
during liposome formation) or actively (i.e., after liposome formation). Hydrophobic drugs 
can be directly combined into liposomes during the formation process. The encapsulation 
efficiency is dependent on the properties of the lipid such as length and packing density as 
well as drug-lipid interactions. Passive loading of hydrophilic drugs depends on the ability of 
liposomes to trap aqueous solution containing a dissolved drug during vesicle formation. 
Only a small percentage of a hydrophilic drug can be encapsulated by passive loading using 
the most common thin film hydration method[33]. The highest encapsulation efficiency by 
means of passive loading (up to 65%) is achieved by the reverse-phase evaporation method. 
However, this technique uses organic solvents, which will leave probably a small amount of 
residual in the liposome suspension, and thus is not feasible for commercial production[23, 33]. 
Compared to passive loading, active loading employing pH gradient methods could achieve 
near 100% encapsulation efficiencies [34, 35]. 
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Due to their biocompatibility and biodegradability, liposomes are considered safer drug 
delivery systems. Both diagnostic and therapeutic agents can be encapsulated into liposomes. 
The encapsulation of drugs into the liposomes protects them against enzymatic degradation 
and immunologic inactivation, thus improves their therapeutic activity. Meanwhile the 
encapsulation minimises exposure of healthy tissue to the drugs during their circulation in the 
blood. Therefore, the systemic toxicity will be largely reduced compared with the free 
drugs[36]. Currently, several liposome-based drugs are approved for clinical practice such as 
Doxyl®[37, 38] and AmBisome®[39]; many others are in the various stages of clinical trials[40-43].  
Quantum dots 
Amongst the various types of nanomaterials, i.e. metals, metal oxides, organic materials or 
biomaterials, semiconductor nanoparticles (NPs), also referred to as quantum dots (QDs), has 
become a major interdisciplinary area of science due to their unique properties [44]. QDs are 
generally considered to be particles of material which have diameters in the range of 1 to 
10nm[45]. The small dimensions of QDs result in properties differing from those seen in the 
corresponding bulk material. These unique physical properties give rise to many potential 
applications in areas such as luminescence, electronics, catalysis, and optoelectronics[46-49]. 
The size of the particle and surface to volume ratio are two fundamental factors of individual 
QD, which are responsible for these unique properties. As a particle becomes smaller the 
band gap gradually becomes larger because of quantum confinement effect. Also, as the size 
of the semiconductor material becomes smaller the ratio of the number of surface atoms to 
those in the interior increases, which leads to the surface playing an important role in the 
properties of the material[50]. Thus, both particle size and the synthetic method determine the 
physical and electronic properties of the QD produced, which gives scientists the unique 
ability to change the electronic and chemical properties of a QD. 
QDs have quite a few advantages over traditional fluorescent organic molecules. They have 
size- and composition-tuneable fluorescence emission from ultra violet to infrared 
wavelengths, narrow spectral line widths, high luminescence quantum efficiency, broad 
absorption profiles, and stability against photo-bleaching[9, 51-53]. The broad absorption and 
narrow emission spectra of QDs allow the simultaneous detection of multiple colours of QDs 
upon illumination with a single light source which is very useful for fluorescent multiplexed 
analysis in biological system[51, 54]. Due to their photophysical characteristics, QDs are 
thought to have potential as novel fluorescent probes for diagnostic purposes[9, 52]. However, 
their biocompatibility and potential toxicity remain critical issues for use in humans and thus 
5	
	
limit their application[55, 56]. The combination of liposome and QDs to create stable and 
multifunctional assemblies could overcome the shortfall of QDs and pave the ways for the 
development of novel drug delivery system. 
Liposome and QD Hybridisation 
QD is an ideal candidate for fluorescent imaging in in both the biomedical and 
pharmaceutical fields. However, QD are mostly synthesised in non-polar organic solvents, 
their surface hydrophobicity or poor colloidal stability at physiological conditions frequently 
renders them inappropriate for biomedical and clinical applications. Many strategies have 
been developed to overcome this limitation, such as functionalisation of QD with peptides, 
antibodies, and polymers[57, 58]. However, evidence shows that the presence of these ligands 
could be disadvantageous for their application. Surface modification often quenches QD 
fluorescence and decreases their photostability[59, 60], which for in vivo applications requires 
higher doses of administered QD and therefore increases potential toxicity. Encapsulation of 
QD within liposomes may avoid the chemical functionalisation of QDs, which can lead to 
enhanced stability in plasma, better control of the pharmacological fate, and an overall 
improvement in their biocompatibility. Moreover, therapeutic agent e.g. anticancer drug 
could also be added to the QD liposome hybrid to create a device with both therapeutic and 
diagnostic functions.  For example, hydrophobic QDs could be embedded in the lipid bilayer, 
whereas hydrophilic therapeutic agents can be encapsulated within the internal liposome 
aqueous core[61, 62]. The hybridisation of the QDs with liposome generates a novel, interesting 
class of nano-range delivery devices, which combines the unique optic properties of QD and 
the lipid functional moiety, thus offering new opportunities in multifunctional drug delivery 
system development. A summary of the types of hybrid delivery systems that could be used 
for simultaneous diagnostics and therapeutics of cancer is presented in Table 1.  
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Table 1 Representative liposome QD hybrid systems for simultaneous imaging and therapy of cancer 
Types of QD used 
Incorporated 
therapeutic 
agent  
Structure of hybrid systems 
Target (tumour) cells or xenografts 
[targeting mechanism/species 
employed] 
Ref. 
Trioctylphosphine 
oxide (TOPO)-coated 
CdSe QDs 
N/A QD inside hydrophobic interior of lipid bilayer 
HEK293 human embryonic kidney 
cells [non-specific internalization] 
[63] 
TOPO-coated 
CdSe/ZnS N/A 
QD inside hydrophobic interior of 
lipid bilayer 
A549 human epithelial lung cells and 
CD-1 nude mice 7 inoculated with 
C33a human cervical carcinoma cells 
[non-specific internalization] 
[64, 65] 
TOPO-coated 
CdSe/ZnS and 
Carboxyl-
functionalised QD 
N/A 
TOPO-QD inside hydrophobic 
interior of lipid bilayer and Carboxyl-
QD inside interior aqueous 
compartment 
HuH-7 human hepatocellular 
carcinoma cells [non-specific 
internalization] 
[66] 
Cetrimonium 
Bromide (CTAB) 
capped CdTe or 
CdHgTe QDs 
N/A QD inside hydrophobic interior of lipid bilayer 
MCF7 human breast carcinoma cells 
and Kunming mice [non-specific 
internalization] 
[67] 
TOPO-coated 
CdSe/ZnS 
Doxorubicin 
(Dox) 
TOPO-QD inside hydrophobic 
interior of lipid bilayer and Dox 
inside interior aqueous compartment 
N/A [61, 62] 
CdSe and CdSe/ZnS 
QDs (Lumidot®) Cisplatin 
QD inside hydrophobic interior of 
lipid bilayer and Cisplatin inside 
interior aqueous compartment 
Melanoma cells and nude mice [non-
specific internalization] 
[68] 
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Dihydroxylipoic acid 
(DHLA)-capped 
CdSe/ZnS QDs 
N/A QD on the surface of liposome 
B16F10 cells and C57BL/6 mice 
[tracking extravasation with QD 
labelled cells] 
[69] 
Carboxyl CdSe/ZnS 
QDs Dox 
QD on the surface of liposome and 
Dox inside interior aqueous 
compartment 
MCF-7/HER2 cells and xenografts 
[anti-HER2 single chain Fv fragments] 
[70] 
Streptavidin 
conjugates CdSe/ZnS 
QDs and ITK-
carboxyl CdSe/ZnS 
QDs 
N/A 
streptavidin-QDs on the surface and 
carboxyl-QD inside interior aqueous 
compartment 
A431 human epidermoid carcinoma 
and CHO Chinese hamster ovary cell 
lines [epidermal growth factor (EGF) 
ligand] 
[71] 
3-mercaptopropionic 
acid (MPA)-capped 
CdTe QDs 
N/A QD inside interior aqueous compartment 
Xenografts [non-specific 
internalization] 
[72] 
thiol-capped CdTe 
QDs N/A 
QD inside interior aqueous 
compartment 
U2OS human osteosarcoma cell, Hela 
human cervical carcinoma cell and 
293T human embryonic kidney cell 
[non-specific internalization] 
[73] 
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Formulation of liposomal QD Hybrid system 
Developing liposome-based drug delivery system with QD-based fluorescence imaging 
requires the hybridisation of QD with liposomes. Figure 1 depicts three different strategies 
for QD incorporation. Hydrophobic QDs have been inserted into the hydrophobic interior of 
the liposomal membrane[61, 63, 64], and hydrophilic QDs have been encapsulated in the interior 
aqueous compartment[66, 71, 74, 75] or on the outer membrane of liposomes[69, 70]. To achieve 
these, different methods have been used, depend on properties of QD. 
 
Figure 1 Quantum dots incorporation models of hybrid delivery systems. A-hydrophobic 
quantum dots encapsulated shell model, B-hydrophilic quantum dots linked shell model, C-
hydrophilic quantum dots encapsulated core model.  
Thin film hydration method is one of the most common techniques used in liposome 
production. Both hydrophobic and hydrophilic molecules can be encapsulated into liposomes 
during the synthesis process. Hydrophobic QDs could be easily incorporated into the lipid 
bilayer when added to the thin lipid film. lipid Vogel and co-workers have incorporated 
hydrophobic TOPO functionalised CdSe QDs into the bilayer membrane of liposome using 
thin film hydration [63]. A high yield of LUV along with some MLV was obtained using this 
approach, which sizes ranged from 50nm to 50µm. The researchers also used electric field 
aided hydration to shorten process time and produced more homogeneous unilamellar 
structures. However, they didn’t show if there was any influence on vesicle size by such 
process and there weren’t any further steps used to reduce the liposome size. In another study, 
Al-Jamal, Al-Jamal, Tian, Lacerda, Bornans, Frederik and Kostarelos [64] encapsulated TOPO 
capped CdSe/ZnS QDs into zwitterionic and cationic lipid bilayer of SUV using thin film 
hydration plus sonication. The incorporation of hydrophobic QDs in the lipid bilayer led to 
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significant enhancement of their optical stability during storage and exposure to UV 
irradiation compared to that of QD alone in toluene. This method was adapted by Tian, Al-
Jamal, Al-Jamal and Kostarelos [61], who not only incorporated QDs into the lipid bilayer, but 
also encapsulated doxorubicin (Dox) into the core of the liposome. The loading of Dox into 
L-QD was done by the osmotic gradient technique and achieved more than 97% loading 
efficiency.  
Unlike encapsulating hydrophobic QD, where thin film hydration is the dominant method[61, 
62, 64, 76-78], there are several different methods to incorporate hydrophilic QD into liposomes. 
First, thin film hydration could also be used for incorporating hydrophilic QD into the 
aqueous core of liposome[72, 74, 75]. Al-Jamal, Al-Jamal, Bomans, Frederik and Kostarelos [74], 
[75] synthesised COOH-PEG-lipid coated L-QDs by thin film hydration followed by 
sonication as they did for the hydrophobic CdSe/ZnS QD. The thin lipid film was prepared 
and was hydrated with QD suspension. SUV were then prepared by further bath sonication. 
Ye, Wang, Li, Yu and Hu [67] have also incorporated hydrophilic CdTe QDs into the vesicle 
lipid bilayer using the classic thin film hydration method. CTAB was used to make 
negatively charged hydrophilic QDs soluble in lipid mixture. Further sonication step was also 
used to form SUV loaded with QDs. Second, Bothun, Rabideau and Stoner [66] used a single 
step reverse phase evaporation method to create a liposomal system that deliver both green 
hydrophobic and red hydrophilic CdSe/ZnS QDs into carcinoma cells. In the reverse phase 
evaporation process, an organic solvent phase containing lipids and the hydrophobic QDs 
was mixed with an aqueous phase containing the hydrophilic QDs to form an emulsion. The 
organic solvent was then removed by rotary evaporation to collapse the emulsion phase and 
drive QD incorporation within the liposome. Hansen, van Emmerik, van Gaal, Storm, van 
Hest and Lowik [79] also used reversed phase evaporation approach and further purified their 
QD-loaded liposome by Ion-exchange method. Third, the detergent dialysis technique was 
also used to encapsulate carboxyl CdSe/ZnS QD into core of the PEGylated liposome[71]. To 
do this, the lipid film was hydrated in Hepes Buffer Saline (HBS) containing both 1-O-N-
Octyl-β-D-glucopyranoside (OGP) detergent and carboxyl CdSe/ZnS QDs. The result 
solution was immediately dialysed against HBS to form hybrid liposome.  
An alternative approach to hybridise hydrophilic QD with liposome is to conjugate the 
particle onto the surface of liposome. Voura, Jaiswal, Mattoussi and Simon [69] combined 
DHLA-capped QDs with the commercially available Lipofectamine 2000. Because the 
liposome consisted of cationic lipids are positive charged and the DHLA-QDs are negatively 
charged, they joined together by electrostatic force.  The L-QD was simply formed by 
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incubation of QD with liposome solution. In another report, Weng, Noble, Papahadjopoulos-
Sternberg, Chen, Drummond, Kirpotin, Wang, Hom, Hann and Park [70] have developed a 
multifunctional L-QD with imaging, targeting, and therapeutic modalities. The liposomes 
were simply prepared by extrusion. The carboxyl CdSe/ZnS QDs were then covalently linked 
to liposomes through a cross-linker. Furthermore, Dox was also encapsulated into the L-QD 
by a gradient loading technique either before or after covalent linking of the QDs to 
liposomes. It is worth to note that lower drug loading efficacy (~30%) was showed when 
drug loaded into liposomes after QD conjugation, which was probably due to the shielding of 
QD on liposome surface. 
Characterisation of liposomal QD hybrid system  
Morphology of liposomal QD hybrid system 
Morphological characterisation of liposomal QD hybrid system helps in understanding the 
relative structure, position of the QD molecules and assembly of the L-QDs. These 
characteristics can influence the stability of the L-QD in vitro as well as in vivo and also can 
impact the bio-distribution. Morphology of QD and liposome complexes can be studied using 
techniques such as, cryogenic transmission electron microscopy (cryo-TEM), freeze fracture 
electron microscopy (ff-EM) and Atomic force microscopy (AFM).  
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Figure 2 (A) Cryo-TEM images of Liposome−QD hybrid vesicles, scale bar 100nm. 
Reproduced with permission from ref. 64. Copyright 2008 American Chemical Society; (B) 
TEM TEM images of the liposome-coated QDs. Reproduced with permission from ref. 72. 
Copyright 2010 Springer; (C) AFM images of empty liposomes; (D) AFM images of (DSPC) 
Liposome-QD hybrid vesicles. Reproduced with permission from ref. 61. Copyright 2011 
Elsevier. 
Using Cryo-TEM Al-Jamal, Al-Jamal, Bomans, Frederik and Kostarelos [74] showed clearly 
that vesicular structures of liposome were formed and that hydrophilic QDs were 
incorporated into the core of vesicle. It was also consistently observed that the QDs were 
interacting with the lipid bilayer rather than being simply encapsulated into the vesicle inner 
aqueous compartment, suggesting some degree of mixing between the bilayer lipids and the 
functional ligands on the QD surface. In a later study, the same group showed several Cryo-
TEM images which indicated that incorporating hydrophobic QD into lipid bilayer with low 
lipid:QD ratios (1000:1) resulted in elongated and deformed vesicular structures. Moreover, 
the lipid bilayer thickened at specific locations, which suggested that the incorporation of QD 
was taking place in “pockets” rather than being evenly distributed throughout the bilayer. 
According to their results, the ideal lipid to QD ratio for L-QD formation is 10000 to 1. At 
this ratio, perfect spherical liposomes were formed, and there was no noticeable physical 
deformation of the liposomes by hydrophobic QDs [64]. In general, hydrophobic QD 
containing liposome showed darker rim than the interior of the vesicles because of the 
presence of the electron-dense QD in the lipid bilayer[64, 77] (Figure 2A). Whereas, in case of 
hydrophilic QD (third model, Figure 1C), TEM images showed a pale edge and dark centre 
of the obtained L-QD, which suggested the QDs were incorporated into the core of 
liposome[72] (Figure 2B). The technique of AFM was used by Tian, Al-Jamal, Al-Jamal and 
Kostarelos [61] to investigated the structural elucidation of the hybrid vesicles. Interestingly, in 
contrast to the liposome control which showed a smooth surface, the image of L-QD showed 
that the incorporation of QD into the lipid bilayers resulted in a rough surface (Figure 2C&D). 
3D image analysis indicated that QD associated with the lipid bilayers and distributed 
throughout the vesicle surface. Furthermore, the cross-section analysis suggested that QD 
incorporation increased the height of the liposome from 8 nm to almost 20 nm. Weng, Noble, 
Papahadjopoulos-Sternberg, Chen, Drummond, Kirpotin, Wang, Hom, Hann and Park [70] 
used ff-EM to characterise the nanoscale structures of the both free carboxyl QDs and when 
conjugated to liposomes outer layer. QDs appeared as small, mostly spherical particles with 
12	
	
shadowing behind the structure, which was typical for hard-core particles. In contrast to QDs, 
liposomes displayed convex and concave fracture planes, which was typical for membrane-
bound structures. The ff-EM images also showed that a small number of QDs appeared on 
liposomal fracture planes, which reflected imprints of surface-attached QDs showing through 
the semifluid, liquid-crystalline bilayers.  
Particle size and surface charge 
Size and size distribution measurements are formulation parameters that indicate 
homogeneity of the particles in liposomal formulations and are very important for 
formulation and process optimisation. The poly-dispersity index (PI) of liposome reflects the 
range of liposome species present around the target average liposome size. In general, 
uniformly sized liposomes with a lower PI (<0.2) are preferred for drug delivery. Moreover, 
changes in the average particle size and PI can be used as indicators of long-term stability. 
Dynamic light scattering (DLS) and transmission electron microscopy (TEM) are the most 
common techniques to determine the size of liposomes. Al-Jamal, Al-Jamal, Bomans, 
Frederik and Kostarelos [74] demonstrated that incorporating of hydrophilic QD into the core 
of liposome largely increased liposome size as determined by both DLS and cryo-TEM. The 
size distribution was wide, as expected from thin film hydration preparation method. The 
surface charge characteristics of the L-QDs were in accordance with the characteristics of the 
lipid molecules used to form the bilayers. Sigot, Arndt-Jovin and Jovin [71] showed a similar 
result from TEM measurement that hydrophilic QD and liposome hybrid was larger than 
empty liposome, and the vesicle size increased with increase number of encapsulated QD. In 
addition, Chu, Zhuo, Xu, Sheng, Hou and Wang [72] noted that hydrophilic QD and liposome 
hybrids in water retain their spherical structures, as well as the most of QDs remain trapped 
within the vesicles even after storing at 4°C for 609 days. This suggested that incorporation 
of QD to the core of liposome not only prevent the QDs being released from the vesicles but 
also reinforce the vesicle structure. Furthermore, Weng, Noble, Papahadjopoulos-Sternberg, 
Chen, Drummond, Kirpotin, Wang, Hom, Hann and Park [70] conjugated hydrophilic QD to 
the surface of liposome, which also resulted in adversely increase of both vesicle size and 
size distribution. Interestingly, for hydrophobic QD and liposome hybrids, Al-Jamal, Al-
Jamal, Tian, Lacerda, Bornans, Frederik and Kostarelos [64] have shown that incorporating 
QDs did not significantly change the size and surface charge of hybrids. The mean L-QD 
diameter and surface charge were in the range of that empty liposomes. Subsequent studies 
carried out in this group have showed that both the size and the surface charge of 
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hydrophobic QD and liposome hybrid vesicles remain almost the same even after Dox 
loading, which is consistent with liposome control. This suggested that the process of 
hydrophilic drug loading does not affect the physicochemical properties of L-QD[62]. The 
same group also demonstrated that such L-QD had pronounced colloidal stability and no 
mean vesicle diameter increase at both 4°C and 25°C over three weeks[61]. However, 
Kethineedi, Crivat, Tarr and Rosenzweig [77] have found that incorporating hydrophobic QD 
slightly increase the size of L-QD from a mean diameter of 75 nm to 100 nm. Zhang, Wen, 
Al-Suwayeh, Yen and Fang [68] has also showed an increase of liposome size with QD and 
cisplatin loading. Such changes also happened on surface charge when incorporating cisplatin 
and QDs into the liposome. The loading of cisplatin or CdSe QDs significantly reduced the 
negative zeta potential, and dual loading further shielded the electric surface potential. Such 
differences may be resulted from different formulations and production procedures used 
among studies.  
Photostability of QDs in the hybrid system 
Photostability of QD after incorporating to the L-QD could be quantitatively studied by 
photoluminescence (PL) spectroscopy [61, 64, 67, 72, 78]. Interestingly, incorporation of QDs 
within the lipid bilayer led to enhanced photostability compared to that of bare QDs [64, 67]. 
Al-Jamal, Al-Jamal, Tian, Lacerda, Bornans, Frederik and Kostarelos [64] showed that the 
spectral characteristics of TOPO–caped CdSe/ZnS QD in obtained MLV and SUV were 
similar to those QDs in toluene. Only 30–40% reduction of the initial fluorescence intensity 
was observed when the QD were embedded within the MLV and SUV lipid bilayers, 
compared to more than 70% loss of fluorescence intensity in the case of QD in toluene 
suspensions. Furthermore, QD in toluene were photochemically unstable when exposed to 
UV light, witnessed as a sharp reduction in fluorescence intensity and a marked blue shift at 7 
days, and a complete loss of fluorescence after 14 days of UV exposure. On the other hand, 
the hybrid exhibited improved photostability after both 7 and 14 days of UV exposure. 
Similar results were obtained by Ye, Wang, Li, Yu and Hu [67]. When incorporating CTAB-
coated CdTe or CdHgTe QD into the lipid bilayer, fluorescence of QD was preserved and the 
photostability was enhanced. After 10 hours exposed to UV light, fluorescent intensity of the 
bare QDs reduced sharply, whereas, only 20–30% reduction was observed in the case of 
encapsulated QD. These results indicated that the L-QD improved the photostability of QD 
on storage and against UV light exposure, which can be attributed to the tight packing of the 
QD within the lipid bilayer. The increased photostability of liposome-encapsulated QDs 
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might be expected to improve their performance as fluorescence markers. In another report, 
photostability of CdSe QD encapsulated in lipid bilayers with different physical state was 
inveistigated[78]. Three phospholipids with different were melting temperature (Tm) were 
used. The PL of CdSe QDs changed in a phospholipid-dependent manner when stored under 
ambient conditions. Their results suggested that the Tm of the lipid membrane controls 
optical and chemical properties of embedded QDs and QDs encapsulated within gel-phase 
lipid bilayer were the most stable. Furthermore, Tian, Al-Jamal, Al-Jamal and Kostarelos [61] 
and Zhang, Wen, Al-Suwayeh, Yen and Fang [68] demonstrated the addition of model drugs to 
the liposomes did not significantly alter the PL of QD which is quite important for such 
multifunctional drug delivery system.  
Encapsulation efficiency  
Encapsulation efficiency (EE) determines the loading of QDs in liposomal hybrid 
formulations. EE is critical as it can be used to optimise the formulation composition as well 
as the manufacturing process. EE is calculated using the following formula:  %!! = !"#$%&'($)*+ !" !"#!$#%&'%("#!"#$#%& !" !"#!$#%&'%("#  × 100 
The initial QD concentration is usually a known concentration determined in the formulation. 
There are two techniques have been used to determine EE namely fluorescence spectroscopy 
(FS) and Thermal lens microscopy (TLM). In the first technique, encapsulated QD 
concentration is estimated using photoluminescence. Percentage EE is then calculating using 
the formula. For example, Wang, Zhao, Wang, Yang and Chen [73] encapsulated water soluble 
thiol-capped CdTe QDs into liposome vesicles by agglomeration. The PL intensities of 
obtained L-QD in solutions were measured with a fluorescence spectrophotometer, and 
compared with that of the initial QDs solution. The PL in L-QD solution was totally come 
from the loaded QDs and no fluorescence self-quenching of the QDs inside the liposomes 
was observed, so that the comparison of PL intensities between the L-QD solution and the 
initial QD solution could estimate the loading content of QDs in L-QD. In this study, 95% EE 
was achieved with a lipid/QDs molar ratio of 0.15:1. The second technique, TLM, was 
developed by Batalla, Cabrera, San Martin-Martinez, Korte, Calderon and Marin [80] which is 
an useful tool for determining EE when quenching of the fluorescence happens after 
liposome encapsulation of the QDs. Self-quenching of QD is quite rare in hydrophobic 
loaded QD liposome hybrid, however it may happen when hydrophilic QD incorporating to 
the liposomes. The methodology of TLM consists in measuring the TL signal amplitude as a 
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function of known QDs concentrations in water, i.e. the calibration curve. Next, the unknown 
concentration of encapsulated QDs is determined using the calibration curve. Then, the 
encapsulation efficiency can be calculated as the ratio of the encapsulated QDs concentration 
versus the initial concentration of QDs mixed with the empty liposomes solution. It was 
found that the optimal EE for encapsulating carboxyl CdSe/ZnS inside aqueous compartment 
of the classic soy lecithin/cholesterol liposomes by thin film hydration method was 36% with 
an initial QDs concentration ranged between 1.25 and 10 nM. The authors suggested that 
TLM not only determine the encapsulation efficiency but also the optimum quantity of the 
initial concentration of QDs to be mixed with liposomes.  
In vitro and in vivo biodistribution of liposomal QD hybrid system 
In vitro and in vivo biodistribution of L-QD could be studied using flow cytometry and 
fluorescence microscopy. Flow cytometry studies help determine the average QD 
fluorescence intensity inside the cells, thus can be used to quantify cellular uptake of QD 
liposome hybrids. For example, cellular bonding and uptake of free QDs and various 
liposomal QD constructs were examined in MCF cells with HER2 overexpression 60 minutes 
post incubation at 37 °C[70]. Flow cytometry studies revealed that the uptake of anti-HER2 L-
QDs in HER2-overexpressing MCF cells was significantly higher than in normal MCF cells. 
In contrast, free carboxyl QDs bound non-specifically to all tested cells. Furthermore, anti-
HER2 L-QDs showed markedly greater uptake vs free QDs or vs non-targeted L-QDs in 
HER2-overexpressing MCF7 cells at matching concentrations. Therefore, reduced amounts 
of QD could be used with anti-HER2 L-QDs to reduce the potential cytotoxicity of QDs. The 
biodistribution of L-QDs was also visualised using confocal microscopy. Free carboxyl QDs 
were observed in close association with the cell surface, while anti-HER2 L-QDs 
accumulated mostly in the perinuclear region of the cells (Figure 3A&B). In addition, 
intravenous administration of L-QDs resulted fluorescence signals were readily detected at 
the tumour site 24 hours post-injection. Interestingly, tumour accumulation of both targeted 
and non-targeted L-QD showed similar results, which suggested that long circulating L-QDs 
localise in tumours predominantly via the EPR effect rather than via antibody-mediated 
targeting[70]. In another study, Kostarelos and co-workers studied intracellular trafficking of 
cationic and zwitterionic L-QD by confocal microscopy[64, 65, 74, 75]. The L-QD intracellular 
signal was found to be time and dose dependent for both L-QD types[64, 74]. It is evident from 
the microscopy images obtained that the cationic L-QD were uptake more efficiently by 
A549 cells, compared to weak negative or neutral surface charge L-QD[64, 74]. Cationic L-QDs 
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were bound to the cell membrane within 1h and internalised throughout the cell volume and 
close to the nucleus after 3h incubation presumably through endosomal uptake[74]. Similar 
results were demonstrated by Bothun, Rabideau and Stoner [66], where fluorescence 
microscopy images showed that cationic L-QDs by HuH-7 was higher than Zwitterionic L-
QD. These studies suggested that the positive charge is a key parameter responsible for 
increased cellular uptake of the liposomal QD hybrid system. In vivo transportation of L-QD 
were investigated using a three-dimensional multicellular tumour spheroids (MCS) cultures 
from melanoma cells (B16F10) [74]. Confocal microscopy images depict strong interaction 
between cationic L-QDs and the MCS. The L-QD localised 30–50-mm deep within the MCS 
mass. However, zwitterionic L-QD with a weak negative surface charge were able to diffuse 
deeper into the spheroids. In vivo uptake and retention of L-QD in Tumour Xenografts were 
also investigated[64, 65, 74, 75]. Intratumorally injection of cationic L-QD gave much stronger 
fluorescence signals than zwitterionic L-QD after both 5 minutes (Figure 3C&D) and 24 
hours[64, 74]. It is suggested that zwitterionic vesicles around 100nm in diameter were leaking 
from the tumour immediately after intratumoral administration, while, cationic delivery 
vesicles of similar size significantly increased tumour retention[81]. This is agreed with the 
liposomal QD hybrid system, where cationic L-QD vesicles were uptaken by tumour cells 
and retained within tumour xenografts 24 hours post-injection, in contrast to zwitterionic L-
QD vesicles that were drained out of the xenografts within 5 min following administration[64, 
74]. In vivo behaviour of L-QD were further investigated following intravenous 
administration[65, 75]. Sharp differences were obtained between the tissue biodistribution of the 
various L-QD types dependent on their lipid composition. Cationic L-QD exhibited rapid 
clearance from blood circulation due to transient lung accumulation. After 24 hours post-
administration, redistribution of the cationic L-QD led to their localisation mainly in the liver 
and spleen is thought to be due to adsorption of negatively charged plasma proteins on the 
surface of the cationic L-QDs hinders the nonspecific interaction with the pulmonary 
endothelium[65]. PEGylated L-QD exhibited improved blood circulation compared to cationic 
L-QD. The gel phase PEGylated L-QD accumulated in the solid tumour very rapidly and 
could be retained at the tumour site for at least 24 hours[75]. Overall, L-QD offers great 
potential for tumour imaging applications. 
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Figure 3 (A) SK-BR-3 cells were treated with free QDs, showing nonspecific association on 
the cell surface (B) SK-BR-3 cells were treated with QD-conjugated anti-HER2 liposomes 
(red fluorescence) for 60 min at 37 °C. QD-conjugated liposomes were internalised in SK-
BR-3 cells. Cell nuclei were stained by DAPI (blue fluorescence). Reproduced with 
permission from ref. 70. Copyright 2008 American Chemical Society. Panels C-D represent 
in vivo tumour xenograft uptake and retention of L−QD hybrid vesicles. Confocal 
microscopy images of human cervical carcinoma (C33a) tumours dissected 5 min after 
intratumoral injection with (C) zwitterionic L−QD and (D) cationic L−QD. Left panels, 
L−QD fluorescence; middle panels, PI-stained nuclei; and right panels, the merged green 
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and red channels. Scale bars are 10 µm. Reproduced with permission from ref. 64. Copyright 
2008 American Chemical Society. 
In vivo degeneration of liposomal QD hybrid system 
Though the in vivo biodistribution of L-QDs is relatively well investigated, there is still a lack 
of knowledge about the degeneration of such delivery system. Biomedical applications 
mainly focus on intravenous injection or oral application routes. Upon injection or ingestion, 
L-QDs come into contact with various complex physiological environments, leading to 
formation of a corona made of various biomolecules[82] which covering the L-QDs[83-86]. So 
for the degeneration process, L-QD should be considered as a system including corona, 
liposome envelope and QDs.  So far the protein corona (PC) has mostly been studied, which 
can either has a stabilising effect or has a destabilising impact[84, 87]. The corona complexes 
are quite stable in plasma, however once they have been untaken into the liver, corona and L-
QD degradation could be triggered[88]. Then the elimination of liposome envelope takes place 
in different ways, such as metabolised by Kupffer cells, splenic macrophages or eliminated 
by the target tissues after their accumulation[10]. Eventually, innermost part of QDs may also 
be degraded, which will be highly dependent on the composition of the QD. For example, 
QDs made of CdSe are known to corrode, and thus release metal ions[89], while Silica QDs 
can be, completely dissolved by hydrolysis[90].  
Application of liposomal QD hybrid system 
In vitro and in vivo bio-imaging  
QDs have been used as imaging agents to overcome many of the limitations of conventional 
contrast agents (i.e. organic dyes). The liposomal QD hybrid system provides further 
improvement of photostability and biocompatibility of QD, which could be used in bio-
imaging applications in vitro and in vivo. Quite a few reports have appeared describing the 
use of such hybrid liposomal devices. For example, Voura, Jaiswal, Mattoussi and Simon [69] 
injected the tail veins of C57BL/6 mice with L-QD labelled B16F10 cells. The author 
demonstrated that QD labelling by L-QD has no detectable toxicity to the labelled cells or the 
host animal. The QD signal was observed in B16F10 cells seeded organs, which suggested 
that metastatic tumour cell extravasation could be tracked using L-QD. In addition, the use of 
a set of L-QDs with difference emission spectra in conjunction with multiphoton and 
emission-scanning microscopy provides the opportunity to simultaneously identify and study 
the interactions of different populations of tumour cells and normal tissue cells within the 
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same animal. In another study, Chu, Zhuo, Xu, Sheng, Hou and Wang [72] used three different 
size of L-QDs for sentinel lymph node (SLN) mapping. The encapsulated CdTe QD had 
near-infrared (NIR) emission band which was ideal for in vivo imaging. The NIR light offers 
great advantages for deep tissue imaging applications, because the NIR light could penetrate 
deeply in living tissues, as well as autofluorescence and absorbance from tissue-intrinsic 
chromophores reach their minima in this range. After intradermally injection of L-QDs, a 
bright red fluorescent spot appeared rapidly in the axillary location of a nude mouse. The 
fluorescent signal was retained for 24 hours post-injection. Ye, Wang, Li, Yu and Hu [67] also 
labelled MCF7 cells with CdTe or CdHgTe QDs encapsulated in liposomes (Figure 3A&B). 
It was found that L-QDs were efficiently internalised by MCF7 cells in a time-dependent 
manner (Figure 3C-E). Meanwhile, no cytotoxic effects were observed when cells exposed to 
the L-QD during the whole incubation period. All these findings suggest that L-QD increased 
biocompatibility and stability of QDs, thus improving the imaging effects for cancer cell 
labelling. Their in vivo imaging study using L-QD containing CdHgTe QDs also 
demonstrated the capability of L-QD for imaging in living animals (Figure 3F-I). In the 
imaging process, strong fluorescence signal throughout the entire body was observed 
immediately after L-QD injection. Within 20 minutes of injection, fluorescence signal 
increased strongly in liver and spleen and decreased sharply from the rest of the body, which 
suggested that L-QDs were taken up mainly in the liver and spleen due to RES effect. In 
addition, the authors showed that the injection of L-QD did not appear to induce significant 
toxicity in living animal. All these findings suggested that the L-QD is a promising tool for in 
vitro and in vivo bio-imaging study. 
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Figure 4 Confocal laser scanning microscopy images of MCF-7 cells incubation with lipid-
QD after different time, top panel-fluorescence channel, bottom panel-bright field, (A): lipid-
CdTe 120 minutes, (B): lipid-CdHgTe 120 minutes, (C): lipid-CdTe 30 minutes, (D): lipid-
CdTe 60 minutes, (E): lipid-CdTe 120 minutes. (F)to(I) represent NIR images of the denuded 
mouse after lipid-CdHgTe was injected via tail vein for 10 seconds, 5, 10 and 20 minutes, 
respectively. Reproduced with permission from ref. 67. Copyright 2013 Springer. 
Multifunctional (therapeutic and diagnostic) delivery devices  
One of the key advantages offered by the QD liposome hybrid system is the versatility of 
potential structural and surface characteristics by selection of different lipid components with 
minimal manipulation of the QD. Also, they offer the possibility to simultaneously 
encapsulate therapeutic agents for the construction of multifunctional (therapeutic and 
diagnostic) delivery devices (Table 1). The first QD liposome theranostic systems was 
developed by Kostarelos and co-authors, who loaded L-QD with Dox using the osmotic 
gradient technique[61]. The PL spectra of Dox-loaded L-QD showed that both Dox and QD 
could be simultaneously detected, indicating the coexistence of both QD and Dox in the 
hybrid vesicle population[62]. The process of Dox loading into hybrid vesicles is further 
investigated at various loading concentrations compared with liposome control. The highest 
loading efficiency in hybrid vesicles was 97% compared with liposome control (99%), which 
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indicated that QD incorporation into the lipid bilayer does not affect Dox loading through the 
lipid membrane of liposomes using the pH-gradient technique. It was also found that high 
Dox loading efficiency was achieved at a certain Dox concentration (>0.5 mM) when Dox 
crystal-like structures were formed. Moreover, the following release study showed that fastest 
Dox release was observed from Egg phosphocholine (EPC)-QD vesicles in serum with 50% 
of Dox released over 6 hours compared with that from DSPC-QD vesicles (< 10%), which 
indicated that Dox release profile from L-QD could be modulated simply by changing lipid 
compositions. In another attempt, Weng et. al. [70] have covalently conjugated hydrophilic 
QD at the outer surface of HER2-targeted liposomes (monoclonal antibody fragments of 
HER2 conjugated to liposomes) and then loaded Dox into the aqueous core of these vesicles 
through ammonium sulfate gradient method. While drug loading into liposomes prior to QD 
conjugation was highly efficient (>90%), drug loading after QD conjugation was largely 
reduced with ∼30% loading efficiency. The obtained L-QDs were relatively stable with 15-
30% Dox lost after cold storage in buffer solution for 2 months. The anticancer activity of the 
Dox-loaded hybrids was evaluated in HER2-overexpressing SK-BR-3 cells. The Dox-loaded 
hybrids showed potent cytotoxicity against SK-BR-3 cells (IC50 ∼ 0.5 µg/mL), which was 
comparable to Dox-loaded liposome without QD (IC50 ∼ 0.7 µg/mL). This result suggested 
that intracellular Dox delivery of the hybrid system was as efficient as the direct permeation 
of free Dox in vitro and also indicated that the HER-2 targeting effect was not compromised 
by QD conjugation. Furthermore, L-QD without dox showed minimal cytotoxicity, 
confirming that anticancer activity was due to Dox and not from the QD liposome carrier 
system. In addition, in vivo properties of L-QD delivery system were studied in nude mice. 
The L-QD exhibited moderately prolonged circulation time, which was greatly prolonged 
over that of free QDs. No weight loss or obvious signs of toxicity were observed on mice 
during study period (3 months). After 24 hours, following intravenous injection (IV), in nude 
mice bearing HER2-overexpressing MCF-7/HER2 xenografts, fluorescence signals were 
readily detected at the tumour site as well as in mononuclear phagocytic system (MPS) 
organs known to mediate liposome clearance (Figure 4A). Tumour fluorescence reached a 
plateau after 24 h, with up to 18±5% of total body fluorescence localising to the tumour 
region. Tissue sections of tumours collected 48 h post-injection showed that L-QD extensive 
accumulation within tumour tissue and intracellularly within tumour cells (Figure 4B). In 
another report, Zheng et. al. [68] have encapsulated both Cisplatin and CdSe/ZnS into 
liposomes using thin film hydration method. The loading of cisplatin is approximately 50% 
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with or without QDs. This suggested incorporation of QDs did not affect the drug entrapment 
efficiency, which is agreed with previous studies. In vitro cytotoxicity assay on melanoma 
cells demonstrated that the L-QD without the drug had no cytotoxic effect on melanoma cells, 
while cisplatin-loaded L-QD showed greater cytotoxicity (22% viability). In vivo bio-imaging 
study showed the possibility to track such theranostic systems by IVIS imaging system after 
and intravenous injection. The QD activity was primarily found in the brain and skin, which 
was also confirmed by ex vivo imaging of organs (Figure 4C-E). The biodistribution of 
cisplatin also showed that the drug accumulation in brain and skin was significant increased 
after loading into QD liposome vesicles as compared to that in the free control. Meanwhile, 
liver and spleen uptake of both QD and cisplatin was significantly reduced after 
encapsulation.  These results suggested that entrapment of QDs and the drug into liposomes 
could protect them against degradation, reduce the RES uptake and enhance their delivery to 
the specific tissue site. All these studies demonstrated the potential of the QD liposome 
hybrid delivery system could be used as a platform for synchronous therapeutic and 
diagnostic modalities. 
Figure 5 (A) In vivo fluorescence imaging of three nude mice bearing MCF-7/HER2 
xenografts implanted in the lower back 30 hours after i.v. injection with anti-HER2 QD-ILs. 
Imaging showed that QD-ILs had localized prominently in tumours as well as in MPS organs. 
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Units: efficiency (the fractional ratio of fluorescence emitted per incident photon). (B) A 5 µm 
section cut from frozen tumour tissues harvested at 48 hours postinjection and examined by 
confocal microscopy. The tumour section was examined in two-colour scanning mode for 
nuclei stained by DAPI (blue) and QD-ILs (red). Reproduced with permission from ref. 70. 
Copyright 2008 American Chemical Society. (C-E) represent fluorescence imaging of 
representative nude mice detected with the IVIS system following an intravenous injection of 
CdSe/ZnS QD-loaded liposomes for 2 hours. The negative control (normal saline treatment) 
mice are represented by the animals placed on the right side of each image. (C) whole-body 
imaging in vivo (open arrow indicates the possible site of the brain; close arrow indicates the 
possible site of the skin), (D) ex vivo imaging of the brain, (E) ex vivo imaging of the skin. 
The scale bar is 1 cm. Reproduced with permission from ref. 68. Copyright 2012 Springer.  
Conclusion and Perspectives 
Liposomal QD hybrid systems have great potential for future clinical use since they are 
designed to integrate the well-established physicochemical and pharmacodynamic properties 
of liposomes with unique photochemical properties of QDs[11]. QDs can be loaded into the 
inner space of a liposome, insertion into the liposomal membrane, or attached onto the 
liposome surface. Careful attention should be paid to stability of such complex systems since 
incorporation of QDs and/or therapeutic agents in a liposome may cause payload leakage or a 
decrease in vivo stability of the liposomal nanostructure. Physical deformation of the 
liposomes could be eliminated by optimisation lipids and QD ratio in preparation formulation. 
In addition, high drug loading could be achieved by gradient method after liposome 
formation (with hydrophobic QD) or before hydrophilic QD attached onto liposome surface. 
For in vitro bio-imaging, the L-QD were shown to be efficiently uptaken by living cells in the 
absence of cell death. For in vivo applications, surface charge and lipid composition are 
important factors for blood circulation and tumour accumulation/retention of L-QDs. For 
example, cationic L-QD were retained much longer than zwitterionic L-QD when 
administrated intratumorally. Whereas, PEGylated gel phase L-QD showed prolonged blood 
circulation than cationic L-QD when administrated intravenously. Much more effort should 
be focused on the in vivo behaviour of such hybrid delivery systems. Further investigations 
are needed to further prolong the L-QD blood circulation time, increase their accumulation in 
tumours and reduce their uptake in liver and spleen. Overall, L-QD offers great potential for 
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tumour imaging applications and could be easily adapted to construct theranostic device 
which achieve both diagnostic and therapeutic functions.  
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